TERRASCEND CORP (TSND.CA) Stock Fundamental Analysis
TSX:TSND - CA88105E1088 - Common Stock
1.57 CAD
+0.01 (+0.64%)
We assign a fundamental rating of 3 out of 10 to TSND. TSND was compared to 35 industry peers in the Pharmaceuticals industry. TSND has a bad profitability rating. Also its financial health evaluation is rather negative. TSND is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TSND has reported negative net income.
In the past year TSND had a positive cash flow from operations.
TSND had negative earnings in 4 of the past 5 years.
In multiple years TSND reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -13.33%, TSND is doing worse than 62.86% of the companies in the same industry.
With a Return On Equity value of -64.65%, TSND is not doing good in the industry: 68.57% of the companies in the same industry are doing better.
Looking at the Return On Invested Capital, with a value of 4.28%, TSND is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.33% | ||
| ROE | -64.65% | ||
| ROIC | 4.28% |
ROA(3y)-24.86%
ROA(5y)-21.32%
ROE(3y)-62.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TSND's Operating Margin of 10.26% is amongst the best of the industry. TSND outperforms 82.86% of its industry peers.
In the last couple of years the Operating Margin of TSND has declined.
TSND has a Gross Margin of 50.46%. This is in the better half of the industry: TSND outperforms 74.29% of its industry peers.
TSND's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.26% | ||
| PM (TTM) | N/A | ||
| GM | 50.46% |
OM growth 3Y-5.82%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.82%
GM growth 5Y37.79%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TSND is destroying value.
TSND has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TSND has been increased compared to 5 years ago.
The debt/assets ratio for TSND is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.75, we must say that TSND is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.75, TSND is in line with its industry, outperforming 51.43% of the companies in the same industry.
The Debt to FCF ratio of TSND is 18.35, which is on the high side as it means it would take TSND, 18.35 years of fcf income to pay off all of its debts.
TSND has a better Debt to FCF ratio (18.35) than 68.57% of its industry peers.
TSND has a Debt/Equity ratio of 1.77. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of TSND (1.77) is worse than 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.77 | ||
| Debt/FCF | 18.35 | ||
| Altman-Z | -0.75 |
ROIC/WACC0.42
WACC10.2%
2.3 Liquidity
A Current Ratio of 1.45 indicates that TSND should not have too much problems paying its short term obligations.
With a Current ratio value of 1.45, TSND is not doing good in the industry: 62.86% of the companies in the same industry are doing better.
TSND has a Quick Ratio of 1.07. This is a normal value and indicates that TSND is financially healthy and should not expect problems in meeting its short term obligations.
TSND has a Quick ratio of 1.07. This is comparable to the rest of the industry: TSND outperforms 45.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.45 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
The earnings per share for TSND have decreased strongly by -39.29% in the last year.
The Revenue for TSND has decreased by -14.80% in the past year. This is quite bad
Measured over the past years, TSND shows a very strong growth in Revenue. The Revenue has been growing by 36.80% on average per year.
EPS 1Y (TTM)-39.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-466.67%
Revenue 1Y (TTM)-14.8%
Revenue growth 3Y13.38%
Revenue growth 5Y36.8%
Sales Q2Q%-16.15%
3.2 Future
TSND is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.08% yearly.
TSND is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.60% yearly.
EPS Next Y56.56%
EPS Next 2Y30.3%
EPS Next 3Y22.74%
EPS Next 5Y13.08%
Revenue Next Year-13.42%
Revenue Next 2Y-4.82%
Revenue Next 3Y-0.88%
Revenue Next 5Y2.6%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TSND. In the last year negative earnings were reported.
Also next year TSND is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TSND is valued a bit cheaper than the industry average as 71.43% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, TSND is valued a bit cheaper than the industry average as 68.57% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.91 | ||
| EV/EBITDA | 12.05 |
4.3 Compensation for Growth
A more expensive valuation may be justified as TSND's earnings are expected to grow with 22.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.3%
EPS Next 3Y22.74%
5. Dividend
5.1 Amount
TSND does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:TSND (8/29/2025, 7:00:00 PM)
1.57
+0.01 (+0.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners42.98%
Inst Owner ChangeN/A
Ins Owners3.71%
Ins Owner ChangeN/A
Market Cap580.48M
Analysts82.5
Price Target1.91 (21.66%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-317.53%
Min EPS beat(2)-614.39%
Max EPS beat(2)-20.66%
EPS beat(4)0
Avg EPS beat(4)-243.78%
Min EPS beat(4)-614.39%
Max EPS beat(4)-20.66%
EPS beat(8)0
Avg EPS beat(8)-269.57%
EPS beat(12)1
Avg EPS beat(12)-371.5%
EPS beat(16)3
Avg EPS beat(16)-184.77%
Revenue beat(2)0
Avg Revenue beat(2)-4.7%
Min Revenue beat(2)-6.15%
Max Revenue beat(2)-3.26%
Revenue beat(4)0
Avg Revenue beat(4)-4.36%
Min Revenue beat(4)-6.15%
Max Revenue beat(4)-2.6%
Revenue beat(8)1
Avg Revenue beat(8)-3.22%
Revenue beat(12)2
Avg Revenue beat(12)-3.34%
Revenue beat(16)2
Avg Revenue beat(16)-6.24%
PT rev (1m)-10%
PT rev (3m)-10%
EPS NQ rev (1m)28.55%
EPS NQ rev (3m)58.33%
EPS NY rev (1m)-12.75%
EPS NY rev (3m)-12.75%
Revenue NQ rev (1m)-11.57%
Revenue NQ rev (3m)-14.6%
Revenue NY rev (1m)-9.11%
Revenue NY rev (3m)-11.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.48 | ||
| P/FCF | 36.91 | ||
| P/OCF | 18.85 | ||
| P/B | 3.58 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.05 |
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)0.04
FCFY2.71%
OCF(TTM)0.08
OCFY5.3%
SpS1.06
BVpS0.44
TBVpS-0.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.33% | ||
| ROE | -64.65% | ||
| ROCE | 6.07% | ||
| ROIC | 4.28% | ||
| ROICexc | 4.54% | ||
| ROICexgc | 11.68% | ||
| OM | 10.26% | ||
| PM (TTM) | N/A | ||
| GM | 50.46% | ||
| FCFM | 4.02% |
ROA(3y)-24.86%
ROA(5y)-21.32%
ROE(3y)-62.74%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-2.11%
ROICexcg growth 5YN/A
ROICexc growth 3Y1.66%
ROICexc growth 5YN/A
OM growth 3Y-5.82%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.82%
GM growth 5Y37.79%
F-Score4
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.77 | ||
| Debt/FCF | 18.35 | ||
| Debt/EBITDA | 4.25 | ||
| Cap/Depr | 54.65% | ||
| Cap/Sales | 3.85% | ||
| Interest Coverage | 1.19 | ||
| Cash Conversion | 45.49% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.45 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z | -0.75 |
F-Score4
WACC10.2%
ROIC/WACC0.42
Cap/Depr(3y)90.87%
Cap/Depr(5y)192.32%
Cap/Sales(3y)7.77%
Cap/Sales(5y)14.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-466.67%
EPS Next Y56.56%
EPS Next 2Y30.3%
EPS Next 3Y22.74%
EPS Next 5Y13.08%
Revenue 1Y (TTM)-14.8%
Revenue growth 3Y13.38%
Revenue growth 5Y36.8%
Sales Q2Q%-16.15%
Revenue Next Year-13.42%
Revenue Next 2Y-4.82%
Revenue Next 3Y-0.88%
Revenue Next 5Y2.6%
EBIT growth 1Y-37.21%
EBIT growth 3Y6.79%
EBIT growth 5YN/A
EBIT Next Year153.22%
EBIT Next 3Y48.84%
EBIT Next 5Y30.79%
FCF growth 1Y177.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.53%
OCF growth 3YN/A
OCF growth 5YN/A